V
39.00
-0.87 (-2.18%)
| 前收盘价格 | 39.87 |
| 收盘价格 | 39.35 |
| 成交量 | 1,603,944 |
| 平均成交量 (3个月) | 1,030,885 |
| 市值 | 3,191,416,832 |
| 价格/销量 (P/S) | 671.45 |
| 股市价格/股市净资产 (P/B) | 29.28 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2024 |
| 营业利益率 (TTM) | -694.43% |
| 稀释每股收益 (EPS TTM) | -2.00 |
| 总债务/股东权益 (D/E MRQ) | 93.73% |
| 流动比率 (MRQ) | 13.03 |
| 营业现金流 (OCF TTM) | -103.77 M |
| 杠杆自由现金流 (LFCF TTM) | -60.08 M |
| 资产报酬率 (ROA TTM) | -28.05% |
| 股东权益报酬率 (ROE TTM) | -78.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Verona Pharma plc | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.25 |
|
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.85% |
| 机构持股比例 | 88.91% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 74.00 (Wells Fargo, 89.74%) | 购买 |
| 中 | 57.00 (46.15%) | |
| 低 | 42.00 (HC Wainwright & Co., 7.69%) | 购买 |
| 平均值 | 57.00 (46.15%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 42.88 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Roth MKM | 10 Jan 2025 | 68.00 (74.36%) | 购买 | 45.20 |
| Truist Securities | 08 Jan 2025 | 57.00 (46.15%) | 购买 | 46.20 |
| Wells Fargo | 08 Jan 2025 | 74.00 (89.74%) | 购买 | 46.20 |
| 05 Nov 2024 | 64.00 (64.10%) | 购买 | 38.39 | |
| Canaccord Genuity | 05 Nov 2024 | 44.00 (12.82%) | 购买 | 38.39 |
| HC Wainwright & Co. | 05 Nov 2024 | 42.00 (7.69%) | 购买 | 38.39 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合